While heterogeneity of high-level HER2 amplification and overexpression is very low (up to 11%) in breast cancer [36], it is moderate (approximately 50%) in gastric adenocarcinoma [37] and (approximately 50%) in urothelial carcinoma [38]. This evidence concerns the gene ERBB2 and urothelial carcinoma.